Research progress of antibody-drug conjugates for advanced breast cancer
10.12354/j.issn.1000-8179.2024.20241188
- VernacularTitle:抗体偶联药物在晚期乳腺癌中的研究进展
- Author:
Guo SENYANG
1
;
Huang WENQIN
1
;
Wang LINGZI
1
;
Song YUHANG
1
;
Zheng HONGMEI
1
;
Wu XINHONG
1
Author Information
1. 湖北省肿瘤医院(华中科技大学同济医学院附属湖北肿瘤医院)乳腺中心,国家临床重点专科建设学科,湖北省乳腺癌临床医学研究中心,武汉市乳腺癌临床医学研究中心,武汉市430079
- Publication Type:Journal Article
- Keywords:
antibody-drug conjugates (ADCs);
advanced breast cancer (ABC);
research progress
- From:
Chinese Journal of Clinical Oncology
2024;51(20):1054-1060
- CountryChina
- Language:Chinese
-
Abstract:
Significant research progress has been made in the development of antibody-drug conjugates (ADCs) for the treatment of ad-vanced breast cancer (ABC),ushering new hope for patients with this refractory disease. Through the conjugation of specific antibodies with highly potent cytotoxic drugs,tumor cells can be precisely targeted and killed while minimizing damage to normal tissues. ADCs such as trastuzumab-emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd),have shown excellent efficacy in the treatment of HER2-positive ABC,significantly prolonging patient survival. Furthermore,ADCs targeting triple-negative breast cancer (TNBC),such as sacituzumab govitecan (SG),have also achieved positive results in clinical trials. With the continuous research,development,and optimization of ADCs,as well as the exploration of combination treatment strategies,ADCs are expected to play an increasingly important role in the treatment of ABC in the future. This article provides an overview of the research progress of ADCs in the treatment of ABC,exploring their efficacy and safety. We aim to offer more treatment options and renewed hope for patients with ABC.
